Highbridge Capital Management’s Regenxbio RGNX Stock Holding History

Highbridge Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-60,000	Closed	-$1.79M	–	1261
2018 Q1	$1.79M	Buy	60,000 +20,000	+50%	+$582K	0.03%	451
2017 Q4	$1.33M	Buy	+40,000	New	+$1.21M	0.02%	481
2017 Q3	–	Sell	-40,000	Closed	-$790K	–	1739
2017 Q2	$790K	Sell	40,000 -10,000	-20%	-$194K	0.01%	622
2017 Q1	$965K	Buy	+50,000	New	+$964K	0.01%	636
2016 Q4	–	Sell	-18,359	Closed	-$258K	–	1542
2016 Q3	$258K	Buy	18,359 +8,142	+80%	+$89.8K	﹤0.01%	1072
2016 Q2	$82K	Buy	+10,217	New	+$113K	﹤0.01%	1319

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Highbridge Capital Management's RGNX Position: Q2 2018 in Review

Highbridge Capital Management sold out of Regenxbio (RGNX) in Q2 2018, closing a stake of 60,000 shares — an estimated $1.79M sold.

Highbridge Capital Management first reported a position in RGNX in Q2 2016 and held it in 6 quarters. The position peaked at $1.79M in Q1 2018. 177 funds tracked by Wall St. Rank hold RGNX as of Q2 2018.

Highbridge Capital Management reported no remaining Regenxbio position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 60,000 Regenxbio shares in Q2 2018, an estimated $1.79M.
Highbridge Capital Management first reported a position in Regenxbio in Q2 2016 and held it in 6 quarters.
Highbridge Capital Management's Regenxbio position peaked at $1.79M in Q1 2018.
177 funds tracked by Wall St. Rank held Regenxbio as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.